Nat Med 19:202208 Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jossang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G et al (2021) Safety, antitumor activity, and T-cell responses in a dose-ranging phase I trial of the oncolytic peptide LTX-315 in patients with solid tumors
Results vary based on adherence to the medical protocol, initial metabolic baseline, and lifestyle factors
How it works: Oral Liposomal BPC + KPV supports gastrointestinal barrier integrity, immune regulation, multi-tissue repair, antimicrobial defense, and inflammatory modulation through the complementary and synergistic mechanisms of its two constituent peptides each operating through distinct but overlapping biological pathways that together provide broader gut-immune and tissue repair coverage than either compound achieves independently
What Happens When Glutathione Gets Depleted